AbbVie Continues to Raise Quarterly Dividend Amid Patent Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 08 2026
0mins
Source: Fool
- Stable Dividend Growth: AbbVie has raised its quarterly dividend every year since becoming independent in 2013, with the latest dividend at $1.73 per share, or $6.92 annually, demonstrating strong cash flow and shareholder returns despite challenges from Humira's patent expiration.
- Sales Driven by New Drugs: Sales from Skyrizi and Rinvoq are projected to reach $50 billion by 2030, having generated $31 billion in 2025, effectively countering the decline in Humira sales and ensuring future profitability for AbbVie.
- Neuroscience Portfolio Growth: AbbVie's neuroscience products, including Vraylar and Botox Therapeutic, have seen low-teens percentage year-over-year growth, supporting the company's financial health despite declines in other areas like oncology and aesthetics treatments.
- Future Dividend Potential: With earnings expected to rise by 45.4% in 2026 and 10.8% in 2027, AbbVie is positioned for larger dividend increases in the future, and while it is still years away from becoming a Dividend King, its growth potential remains significant.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 224.950
Low
223.00
Averages
252.00
High
289.00
Current: 224.950
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie’s TrenibotE Program Receives FDA Complete Response Letter
- FDA Response Overview: AbbVie received a Complete Response Letter from the FDA in April 2026 regarding its biologics license application for TrenibotE, highlighting manufacturing-related concerns and requesting additional information, with no safety or efficacy issues raised.
- Product Characteristics Analysis: TrenibotE, a novel botulinum neurotoxin serotype E neuromodulator, is characterized by a rapid onset of effects, reported as early as eight hours post-administration, and a short duration of approximately two to three weeks, potentially appealing to patients wary of long-term commitments.
- Market Potential Exploration: Given that most aesthetic neuromodulators currently in use are based on botulinum toxin type A, TrenibotE's rapid onset may introduce a new direction in the field, catering to consumer demand for shorter-acting products.
- Company Outlook: AbbVie focuses on developing and marketing therapies across immunology, oncology, and neuroscience, and despite facing FDA challenges, the company is confident in its ability to promptly address the FDA's comments and continue advancing TrenibotE towards market approval.
See More
Analysis of VOOG ETF's 52-Week Price Fluctuations
- Price Range Analysis: VOOG ETF's 52-week low is $62.7167 per share and high is $85.3465, with the latest trade at $80.95, indicating relative stability in a volatile market, potentially attracting investors seeking steady returns.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and make more informed investment decisions.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs with significant inflows or outflows, where inflows necessitate purchasing underlying assets, while outflows may lead to selling, affecting the ETF's components.
See More
Eli Lilly Solidifies Leadership in Obesity Drug Market
- Clinical Trial Data Released: Eli Lilly presented detailed clinical trial data for its experimental drug retatrutide at the American Diabetes Association meeting, confirming that its once-weekly injection offers superior weight loss prospects compared to existing medications, further solidifying its leadership in the obesity drug market.
- Increasing Market Competition: While Lilly maintains a leading position, new data from Roche, AstraZeneca, and Pfizer indicates intensifying competition in the obesity drug market, which may lead to price reductions and more options, potentially impacting Lilly's market share.
- Diverse Patient Choices: Roche's enicepatide demonstrated a 22.7% weight loss in mid-stage trials, while both Lilly and Novo Nordisk are committed to providing multiple drug options to cater to diverse patient needs, emphasizing the importance of personalized treatment.
- Challenges in Side Effect Management: Despite breakthroughs in weight loss efficacy, many drugs still face significant side effect issues, particularly gastrointestinal discomfort associated with GLP-1 and GIP hormones, leading to discontinuation rates as high as 40%, posing challenges for market acceptance of these therapies.
See More
AbbVie to Showcase New Blood Cancer Research Data at EHA 2026 Congress
- Clinical Data Showcase: AbbVie will present 21 oral and poster presentations at the EHA 2026 Congress, covering various blood cancer studies including multiple myeloma and chronic lymphocytic leukemia, demonstrating its robust research capabilities in the hematologic oncology space and further solidifying its market position.
- Innovative Drug Advancement: The research includes the investigational drug etentamig (ABBV-383) alongside approved therapies EPKINLY® and VENCLEXTA®, with clinical advancements that could provide new treatment options for patients, enhancing treatment efficacy and quality of life.
- Raising Treatment Standards: AbbVie's research aims to elevate standards of care in blood cancer treatment, with VP Daejin Abidoye stating that the company's ongoing innovations will help address significant challenges in treating hematologic cancers, pushing the industry forward.
- Future Outlook: By showcasing its findings at the EHA Congress, AbbVie not only highlights its research achievements in blood cancers but also reaffirms its commitment to future treatment solutions, potentially attracting increased investor interest in its development pipeline.
See More
AbbVie: A Steady Dividend Growth Stock
- Dividend Growth History: Since going public in 2013, AbbVie has increased its quarterly cash dividend from $0.40 to $1.73 per share, reflecting an annualized growth rate of nearly 12%, underscoring its tradition as a reliable dividend stock.
- Dividend Yield: Currently, AbbVie offers a forward dividend yield of around 3%, providing a relatively high yield given its share price, while trading at approximately 16 times forward earnings, which remains attractive compared to peers.
- Earnings Expectations: AbbVie is projected to report adjusted earnings of $10 per share in 2025, increasing to $16.23 per share by 2027, indicating strong earnings growth potential, especially as competitors like Pfizer face expected declines.
- Sustainable Dividend Policy: With a payout ratio of 42%, AbbVie operates within sustainable levels, and its recent dividend growth averaging 5% to 6% suggests the likelihood of continued increases, appealing to long-term investors.
See More
AbbVie: A Steady Dividend Growth Star
- Dividend Growth History: Since going public in 2013, AbbVie has increased its quarterly cash dividend from $0.40 to $1.73 per share, reflecting an annualized growth rate of nearly 12%, underscoring its tradition as a reliable dividend stock.
- Current Dividend Yield: AbbVie currently offers a forward dividend yield of approximately 3%, providing a relatively high return at its share price level, which appeals to income-seeking investors.
- Strong Earnings Outlook: AbbVie is expected to report adjusted earnings of around $10 per share in 2025, increasing to $16.23 per share by 2027, indicating the company's ability to achieve earnings growth despite facing a patent cliff, which boosts investor confidence.
- Sustainable Payout Ratio: With a payout ratio of 42%, AbbVie remains within sustainable levels, and combined with recent dividend growth averaging 5% to 6%, it suggests the company can continue to increase dividends, attracting long-term investors.
See More
AbbVie’s TrenibotE Program Receives FDA Complete Response Letter
- FDA Response Overview: AbbVie received a Complete Response Letter from the FDA in April 2026 regarding its biologics license application for TrenibotE, highlighting manufacturing-related concerns and requesting additional information, with no safety or efficacy issues raised.
- Product Characteristics Analysis: TrenibotE, a novel botulinum neurotoxin serotype E neuromodulator, is characterized by a rapid onset of effects, reported as early as eight hours post-administration, and a short duration of approximately two to three weeks, potentially appealing to patients wary of long-term commitments.
- Market Potential Exploration: Given that most aesthetic neuromodulators currently in use are based on botulinum toxin type A, TrenibotE's rapid onset may introduce a new direction in the field, catering to consumer demand for shorter-acting products.
- Company Outlook: AbbVie focuses on developing and marketing therapies across immunology, oncology, and neuroscience, and despite facing FDA challenges, the company is confident in its ability to promptly address the FDA's comments and continue advancing TrenibotE towards market approval.
See More
Analysis of VOOG ETF's 52-Week Price Fluctuations
- Price Range Analysis: VOOG ETF's 52-week low is $62.7167 per share and high is $85.3465, with the latest trade at $80.95, indicating relative stability in a volatile market, potentially attracting investors seeking steady returns.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and make more informed investment decisions.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs with significant inflows or outflows, where inflows necessitate purchasing underlying assets, while outflows may lead to selling, affecting the ETF's components.
See More
Eli Lilly Solidifies Leadership in Obesity Drug Market
- Clinical Trial Data Released: Eli Lilly presented detailed clinical trial data for its experimental drug retatrutide at the American Diabetes Association meeting, confirming that its once-weekly injection offers superior weight loss prospects compared to existing medications, further solidifying its leadership in the obesity drug market.
- Increasing Market Competition: While Lilly maintains a leading position, new data from Roche, AstraZeneca, and Pfizer indicates intensifying competition in the obesity drug market, which may lead to price reductions and more options, potentially impacting Lilly's market share.
- Diverse Patient Choices: Roche's enicepatide demonstrated a 22.7% weight loss in mid-stage trials, while both Lilly and Novo Nordisk are committed to providing multiple drug options to cater to diverse patient needs, emphasizing the importance of personalized treatment.
- Challenges in Side Effect Management: Despite breakthroughs in weight loss efficacy, many drugs still face significant side effect issues, particularly gastrointestinal discomfort associated with GLP-1 and GIP hormones, leading to discontinuation rates as high as 40%, posing challenges for market acceptance of these therapies.
See More
AbbVie to Showcase New Blood Cancer Research Data at EHA 2026 Congress
- Clinical Data Showcase: AbbVie will present 21 oral and poster presentations at the EHA 2026 Congress, covering various blood cancer studies including multiple myeloma and chronic lymphocytic leukemia, demonstrating its robust research capabilities in the hematologic oncology space and further solidifying its market position.
- Innovative Drug Advancement: The research includes the investigational drug etentamig (ABBV-383) alongside approved therapies EPKINLY® and VENCLEXTA®, with clinical advancements that could provide new treatment options for patients, enhancing treatment efficacy and quality of life.
- Raising Treatment Standards: AbbVie's research aims to elevate standards of care in blood cancer treatment, with VP Daejin Abidoye stating that the company's ongoing innovations will help address significant challenges in treating hematologic cancers, pushing the industry forward.
- Future Outlook: By showcasing its findings at the EHA Congress, AbbVie not only highlights its research achievements in blood cancers but also reaffirms its commitment to future treatment solutions, potentially attracting increased investor interest in its development pipeline.
See More
AbbVie: A Steady Dividend Growth Stock
- Dividend Growth History: Since going public in 2013, AbbVie has increased its quarterly cash dividend from $0.40 to $1.73 per share, reflecting an annualized growth rate of nearly 12%, underscoring its tradition as a reliable dividend stock.
- Dividend Yield: Currently, AbbVie offers a forward dividend yield of around 3%, providing a relatively high yield given its share price, while trading at approximately 16 times forward earnings, which remains attractive compared to peers.
- Earnings Expectations: AbbVie is projected to report adjusted earnings of $10 per share in 2025, increasing to $16.23 per share by 2027, indicating strong earnings growth potential, especially as competitors like Pfizer face expected declines.
- Sustainable Dividend Policy: With a payout ratio of 42%, AbbVie operates within sustainable levels, and its recent dividend growth averaging 5% to 6% suggests the likelihood of continued increases, appealing to long-term investors.
See More
AbbVie: A Steady Dividend Growth Star
- Dividend Growth History: Since going public in 2013, AbbVie has increased its quarterly cash dividend from $0.40 to $1.73 per share, reflecting an annualized growth rate of nearly 12%, underscoring its tradition as a reliable dividend stock.
- Current Dividend Yield: AbbVie currently offers a forward dividend yield of approximately 3%, providing a relatively high return at its share price level, which appeals to income-seeking investors.
- Strong Earnings Outlook: AbbVie is expected to report adjusted earnings of around $10 per share in 2025, increasing to $16.23 per share by 2027, indicating the company's ability to achieve earnings growth despite facing a patent cliff, which boosts investor confidence.
- Sustainable Payout Ratio: With a payout ratio of 42%, AbbVie remains within sustainable levels, and combined with recent dividend growth averaging 5% to 6%, it suggests the company can continue to increase dividends, attracting long-term investors.
See More
